Catalyst Dossier · compiled by CeliA 🧫
Recordati S.p.A. (REC.MI)
Pharmaceutical Preparations · market cap $11.3B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-01-15 (est.)
Phase 2
Pipeline
16
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Recordati S.p.A. (REC.MI) is an Italian specialty pharmaceutical company with approximately 4,700 employees and a market capitalization of ~$11.3B. The company operates a diversified pipeline spanning urology, oncology-supportive care, rare diseases, endocrinology, ophthalmology, and cardiovascular indications, with multiple assets in Phase 2 and Phase 3. No near-term binary catalysts are flagged in the current calendar.
The catalyst path
- 2027-01-15 (est.)Phase 2 · Osilodrostat 1 MGimp 7/10
- 2027-02-15 (est.)Phase 2 · Pasireotideimp 7/10
- 2027-07-21 (est.)Phase 2 · LCI699imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Silodosin | Phase 3 | Benign Prostatic Hyperplasia |
| Methadone | Phase 3 | Pain Related to Cancer |
| Udonitrectag | Phase 2 | Neurotrophic Keratitis |
| osilodrostat | Phase 2 | Cushing's Syndrome |
| Lercanidipine | Phase 2 | Essential Hypertension |
| Rec 0/0438 1 mg or Rec 0/0438 2 mg | Phase 2 | Neurogenic Detrusor Overactivity |
| Mercaptamine | Phase 3 | Cystinosis |
| Pasireotide Diaspartate | Phase 2 | Post-Bariatric Hypoglycemia |
| LCI699 | Phase 2 | Cushing Syndrome |
| Pasireotide Long Acting Release (LAR) | Phase 2 | Neuroendocrine Tumors |
| Dinutuximab Beta, Zoledronic acid, Interleukin-2 | Phase 2 | Leiomyosarcoma |
| Pasireotide | Phase 2 | Prolactin-Producing Pituitary Tumor |
| Osilodrostat 1 MG | Phase 2 | Mild Autonomous Cortisol Secretion |
| Hemin | Phase 2 | Gastroparesis |
| Siltuximab | Phase 2 | Multiple Myeloma |
| Erenumab-Aooe | Phase 2 | Schwannomatosis |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for REC.MI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 16 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.